Idorsia Pharmaceuticals UK Ltd.: New research reveals chronic insomnia disorder costs UK economy up to £34billion per year

First of its kind research indicates that if chronic insomnia disorder (CID) was treated effectively and comprehensively across the working age population, it could increase the GDP in the UK

Related Keywords

London , City Of , United Kingdom , United States , Germany , Zurich , Züsz , Switzerland , Australia , America , American , British , Swiss , Dennis Riedl , Yerushalmie Troxel , Santa Monica , Robert Moore , Marco Hafner , Kevin Bampton , Idorsia Ltd , American Psychiatric Association , International Classification Of Sleep Disorders , Organisation For Economic , British Occupational Hygiene Society , Institute For Employment Research , University Of Freiburg , Senior Research Leader , Swiss Exchange , American Academy Of Sleep Medicine , Impacts Task , Idorsia Pharmaceuticals Ltd , Idorsia United Kingdom Ltd , University Of Zurich , International Study , World Sleep Day , Idorsia United Kingdom , Idorsia Pharmaceuticals , Gross Domestic Product , Wellbeing Adjusted Life Year , United Kingdom Treasury , Quality Adjusted Life Year , General Manager , Economic Burden , Economic Co Operation , Western Europe , North America , Why Sleep Matters , Economic Costs , Employment Research , Chief Executive Officer , International Classification , Sleep Disorders , American Academy , Sleep Medicine , Statistical Manual , Mental Disorders , Rev Dis , Supplementary Green Book , Discov Today Dis , Idorsia , Pharmaceuticals , Research , Eveals , Hronic , Insomnia , Disorder , Costs , Economy , 454billion , Ear ,